Imperial College London
Alternate

Professor Julian Teare

Faculty of Medicine, Department of Surgery & Cancer

Emeritus Professor
 
 
 
//

Contact

 

+44 (0)20 3312 1072j.teare

 
 
//

Location

 

CL3 026St Marys Multiple BuildingsSt Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Ruban:2022:10.1097/sla.0000000000004980,
author = {Ruban, A and Miras, AD and Glaysher, MA and Goldstone, AP and Prechtl, CG and Johnson, N and Chhina, N and Al-Najim, W and Aldhwayan, M and Klimowska-Nassar, N and Smith, C and Lord, J and Li, JV and Flores, L and Al-Lababidi, M and Dimitriadis, GK and Patel, M and Moore, M and Chahal, H and Ahmed, AR and Cousins, J and Aldubaikhi, G and Glover, B and Falaschetti, E and Ashrafian, H and Roux, CWL and Darzi, A and Byrne, JP and Teare, JP},
doi = {10.1097/sla.0000000000004980},
journal = {Annals of Surgery},
pages = {440--447},
title = {Duodenal-Jejunal Bypass Liner for the management of Type 2 Diabetes Mellitus and Obesity},
url = {http://dx.doi.org/10.1097/sla.0000000000004980},
volume = {275},
year = {2022}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - <jats:sec>            <jats:title>Objective:</jats:title>            <jats:p>The aim of this study was to examine the clinical efficacy and safety of the duodenal-jejunal bypass liner (DJBL) while in situ for 12months and for 12months after explantation.</jats:p>          </jats:sec>          <jats:sec>            <jats:title>Summary Background Data:</jats:title>            <jats:p>This is the largest randomized controlled trial (RCT) of the DJBL, a medical device used for the treatment of people with type 2 diabetes mellitus (T2DM) and obesity. Endoscopic interventions have been developed as potential alternatives to those not eligible or fearful of the risks of metabolic surgery.</jats:p>          </jats:sec>          <jats:sec>            <jats:title>Methods:</jats:title>            <jats:p>In this multicenter open-label RCT, 170 adults with inadequately controlled T2DM and obesity were randomized to intensive medical care with or without the DJBL. Primary outcome was the percentage of participants achieving a glycated hemoglobin reduction of ≥20% at 12months. Secondary outcomes included weight loss and cardiometabolic risk factors at 12 and 24months.</jats:p>          </jats:sec>          <jats:sec>            <jats:title>Results:</jats:title>            <jats:p>There were no significant differences in the percentage of patients achieving the primary outcome between both groups at 12months [DJBL 54.6% (n = 30) vs control 55.2% (n = 32); odds ratio (OR) 0.93, 95% confidence interval (CI): 0.44–2.0; <jats:italic toggle="yes">P</jats:italic> = 0.85]. Twenty-four percent (n = 16) patients achieved ≥15% weight loss in the DJBL group compared to 4% (n = 2) in the controls at 12months (OR 8.3, 95% CI: 1.8–39; <jats:italic toggle="yes">P</jats:italic>=.007). The DJBL grou
AU  - Ruban,A
AU  - Miras,AD
AU  - Glaysher,MA
AU  - Goldstone,AP
AU  - Prechtl,CG
AU  - Johnson,N
AU  - Chhina,N
AU  - Al-Najim,W
AU  - Aldhwayan,M
AU  - Klimowska-Nassar,N
AU  - Smith,C
AU  - Lord,J
AU  - Li,JV
AU  - Flores,L
AU  - Al-Lababidi,M
AU  - Dimitriadis,GK
AU  - Patel,M
AU  - Moore,M
AU  - Chahal,H
AU  - Ahmed,AR
AU  - Cousins,J
AU  - Aldubaikhi,G
AU  - Glover,B
AU  - Falaschetti,E
AU  - Ashrafian,H
AU  - Roux,CWL
AU  - Darzi,A
AU  - Byrne,JP
AU  - Teare,JP
DO  - 10.1097/sla.0000000000004980
EP  - 447
PY  - 2022///
SN  - 0003-4932
SP  - 440
TI  - Duodenal-Jejunal Bypass Liner for the management of Type 2 Diabetes Mellitus and Obesity
T2  - Annals of Surgery
UR  - http://dx.doi.org/10.1097/sla.0000000000004980
VL  - 275
ER  -
Download